Fig. 2.

MGMT expression assessed by immunohistochemistry. Overall survival (A) and first‐line progression‐free survival (B) represented through Kaplan–Meier curves according to MGMT status assessed by IHC in the Italian cohort. Patients with negative MGMT expression (blue) showed significantly worse overall survival (A) and progression‐free survival with first‐line systemic treatment (B), as compared with patients with positive MGMT expression (red). Dotted lines indicate the median survival time. MGMT, O ⁶‐methylguanine‐DNA methyltransferase. [Colour figure can be viewed at wileyonlinelibrary.com]